Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia
Status:
Unknown status
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
Open label study at a single research center. Subjects meeting inclusion and exclusion
criteria will receive 6.5 mg prasterone vaginal inserts daily for twenty weeks. A physical
examination and vulvoscopy with photography of the vulva, vestibule, urethral meatus and
vagina will be performed at baseline and every 4 weeks for 20 weeks. Pain diaries will be
completed between visits.